Status:
COMPLETED
Impact of CYP2C19*17 on the Pharmacokinetics of Proguanil and Clopidogrel
Lead Sponsor:
University of Southern Denmark
Conditions:
CYP2C19 Genotypes
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The aim of this study is to investigate if the genetic variant CYP2C19\*17 affects the pharmacokinetics of proguanil and clopidogrel.
Eligibility Criteria
Inclusion
- Healthy volunteers
- Written consent
- Age 18-65
- CYP2C19\*1 and or CYP2C19\*17 genotype.
Exclusion
- Daily medication
- Alcohol abuse
- Pregnancy
- Breastfeeding
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2013
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT01456546
Start Date
October 1 2011
End Date
July 1 2013
Last Update
July 3 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Pharmacology, University of Southern Denmark
Odense, Fyn, Denmark, DK-5000